Harnessing the Embryo Antitumor Factor NEPN for Broad-Spectrum Cancer Immunotherapy via Dual Modulation of Tumor Progression and Immune Suppression
Kim, K.; Chang, T.-P.
Show abstract
Modifying the tumor microenvironment to target malignant cells and spare healthy cells may be an alternative approach to cancer therapy. Early-stage embryos have been shown to reprogram metastatic tumor cells and prevent tumor formation of several types of cancers, including melanoma, leukemia, and neuroblastoma. However, embryonic factors that suppress tumors in early embryos have not been identified. Here we show that the embryonic secretory factor NEPN suppresses cancer progression and enhances tumor-infiltrating T cells by modulating HSP27 and ARG1 through TGF{beta}1 signaling, together with broader regulation of tumor-promoting and immune-modulating cytokines. Importantly, NEPN strengthens immune responses and cell death in not only non-solid tumor but also solid tumors by increasing T cell infiltration and activity in the tumor microenvironment. The ability of NEPN to boost immune responses within the tumor microenvironment establishes it as a promising therapeutic candidate for cancer immunotherapy.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Regulatory T cells crosstalk with tumor and endothelium through lymphotoxin signaling 97%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 97%
- Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 97%
Similar papers in this journal
- Metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization 96%
- Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs 96%
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 95%
Similar papers in this journal
- Transcriptional Control of Brain Tumour Stem Cell by a Carbohydrate Binding Protein 96%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 96%
- Cancer-cell-derived cGAMP limits the activity of tumor-associated CD8+ T cells 96%
Similar papers in this journal
- Suppression of tumor/host intrinsic CMTM6 drives anti-tumor cytotoxicity in a PD-L1 independent manner 96%
- Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma 96%
- Combining an alarmin HMGN1 peptide with PD-L1 blockade facilitates stem-like CD8+ T cell expansion and results in robust antitumor effects 96%
Similar papers in this journal
- A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma 96%
- EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes 96%
- Systematic analysis uncovers SYK dependency in NF1LoF melanoma cells 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.